SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001493152-25-001147 from Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899) (PTIX)

Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899)
Date: Jan. 7, 2025 · CIK: 0001022899 · Accession: 0001493152-25-001147

AI Filing Summary & Sentiment

File numbers found in text: 333-280244

Date
June 14, 2024
Author
Chief
Form
CORRESP
Company
Protagenic Therapeutics, Inc.\new (PTIX, PTIXW) (CIK 0001022899)

Letter

Protagenic Therapeutics, Inc.

Fifth Avenue

New York, NY 10010

January 7, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, DC 20549

Re: Protagenic Therapeutics, Inc.

Registration Statement on Form S-3

Originally filed June 14, 2024, as amended on January 7, 2025

File No. 333-280244

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Protagenic Therapeutics, Inc. (the “Company”), the undersigned hereby requests that the Company’s Registration Statement on Form S-3 (File No. 333-280244) originally filed with the U.S. Securities and Exchange Commission (the “Commission”) on June 14, 2024, and amended on January 7, 2025 (the “Registration Statement”), be declared effective on January 8, 2025, at 5:00 pm, Eastern Standard Time, or as soon as practicable thereafter.

Very
truly yours,
PROTAGENIC
THERAPEUTICS, INC.

Show Raw Text
CORRESP
1
filename1.htm

Protagenic
Therapeutics, Inc.

149
Fifth Avenue

New
York, NY 10010

January
7, 2025

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

    Re:
    Protagenic
                                            Therapeutics, Inc.

    Registration
    Statement on Form S-3

    Originally
    filed June 14, 2024, as amended on January 7, 2025

    File
    No. 333-280244

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933 and on behalf of Protagenic Therapeutics, Inc. (the “Company”), the undersigned
hereby requests that the Company’s Registration Statement on Form S-3 (File No. 333-280244) originally filed with the U.S. Securities
and Exchange Commission (the “Commission”) on June 14, 2024, and amended on January 7, 2025 (the “Registration Statement”),
be declared effective on January 8, 2025, at 5:00 pm, Eastern Standard Time, or as soon as practicable thereafter.

    Very
    truly yours,

    PROTAGENIC
    THERAPEUTICS, INC.

    By:
    /s/
    Alexander K. Arrow

    Alexander
                                            K. Arrow

    Chief
    Financial Officer

cc:
Dean Colucci, Duane Morris LLP